# WellmarkerBio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wellmarkerbio-co

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: www.wmbio.co
- Total disclosed funding: $56M
- Latest round: Series C (Aug 28, 2021)
- Investors on record: 22

## About

WellmarkerBio Co., Ltd. is a South Korean biotechnology company dedicated to developing innovative cancer therapies using predictive biomarkers, aiming to enhance treatment efficacy and precision for oncology patients.Founded in 2016, WellmarkerBio Co., Ltd. operates from its headquarters in Seoul, South Korea. The company focuses on the development of oncology drugs and has raised a total of KRW 14 billion in SERIES C funding in August 2021 to support its mission. The latest funding round involved various investors, including Magellan Technology Investment and GeneN Investment Partners. The founder's history and details about previous ventures remain unspecified.WellmarkerBio specializes in the development of innovative cancer therapies through the use of predictive biomarkers. Their core offerings include First-in-Class oncology drugs designed to assess therapeutic efficacy before treatment. The company collaborates with institutions such as Seoul Asan Medical Center to ensure that their research aligns with real-world effectiveness, targeting markets in South Korea and the United States to deliver advanced therapeutic solutions to healthcare providers.In 2023, WellmarkerBio reported revenue of KRW 64,957.3 mn, with an EBITDA of KRW -6,464,469.1 mn. The company's revenue model is centered around B2B partnerships with healthcare providers, leveraging licensing agreements and collaborations to integrate their predictive biomarker technology into treatment protocols, thereby enhancing accessibility to their innovative therapies.WellmarkerBio plans to advance its product portfolio by launching new therapies designed for specific cancer types, although specific release dates are currently unavailable. The company aims to expand into additional markets beyond South Korea and the United States, focusing on regions where precision oncology is gaining traction. The recent funding of KRW 14 billion from the SERIES C round will be utilized to support these product developments and market expansions.

## Funding rounds

- Series C, Aug 28, 2021, $12M — Seoul Investment Partners, Magellan Technology Investment, LS Securities, S&S Investment, GeneN Investment Partners, Elohim Partners, GTOG Private Equity
- Series B, Jul 6, 2019, $15M — HB Investment, Mirae Asset Venture Investment, NH Investment & Securities, Sun&Tree Asset Management, Orbit Partners, Brick Investment
- Series A, Nov 1, 2018, $25M — Korea Development Bank, Meritz Securities, Mirae Asset Venture Investment, IBK Capital, Magellan Technology Investment, The Wells Investment, KB Securities, Widwin Investment, GAIA Venture Partners, Friend Investment Partners, Yozma Group Korea
- Seed, Apr 3, 2018, $1.8M — NH Investment & Securities
- Seed, Feb 20, 2018, $2.3M — GAIA Venture Partners

## Investors

- GAIA Venture Partners (https://capitalatlas.ai/funds/gaia-venture-partners) — Seed, Series A
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Seed, Series B
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series A
- Meritz Securities — Series A
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series A, Series B
- IBK Capital (https://capitalatlas.ai/funds/ibk-capital) — Series A
- Magellan Technology Investment (https://capitalatlas.ai/funds/magellan-technology-investment) — Series A, Series C
- The Wells Investment (https://capitalatlas.ai/funds/the-wells-investment) — Series A
- KB Securities (https://capitalatlas.ai/funds/kb-securities) — Series A
- Widwin Investment (https://capitalatlas.ai/funds/widwin-investment) — Series A
- Friend Investment Partners (https://capitalatlas.ai/funds/friend-investment-partners) — Series A
- Yozma Group Korea (https://capitalatlas.ai/funds/yozma-group-korea) — Series A
- HB Investment (https://capitalatlas.ai/funds/hb-investment) — Series B
- Sun&Tree Asset Management — Series B
- Orbit Partners (https://capitalatlas.ai/funds/orbit-partners) — Series B
- Brick Investment (https://capitalatlas.ai/funds/brick-investment) — Series B
- Seoul Investment Partners (https://capitalatlas.ai/funds/seoul-investment-partners) — Series C
- LS Securities — Series C
- S&S Investment (https://capitalatlas.ai/funds/s-s-investment) — Series C
- GeneN Investment Partners (https://capitalatlas.ai/funds/genen-investment-partners) — Series C
- Elohim Partners (https://capitalatlas.ai/funds/elohim-partners) — Series C
- GTOG Private Equity (https://capitalatlas.ai/funds/gtog-private-equity) — Series C